Fetuin-A, a Promising Serum Biomarker for Diagnosis of Non-Alcoholic Fatty Liver Disease - Trial NCT06097039
Access comprehensive clinical trial information for NCT06097039 through Pure Global AI's free database. This phase not specified trial is sponsored by Zagazig University and is currently Enrolling by invitation. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zagazig University
Timeline & Enrollment
N/A
Aug 01, 2023
Jan 20, 2024
Primary Outcome
To assess fetuin-A serum concentration,To measure liver stiffness and fibrosis degree,Number of participants with fetuin-A serum concentration and liver stiffness degree using FibroScan
Summary
The work investigate the role of fetuin-A in the diagnosis and assessment of the severity of
 non-alcoholic fatty liver disease (NAFLD).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06097039
Device Trial